8-K: Rhythm Pharma Q3 Revenue Up, FDA Decision Nears for HO

Rhythm Pharmaceuticals reported strong third-quarter 2025 revenue growth for IMCIVREE, driven by Bardet-Biedl syndrome sales, and anticipates an FDA decision for acquired hypothalamic obesity by December 20, 2025.

Summary

• Net product revenue from global sales of IMCIVREE was $51.3 million for the third quarter of 2025, an increase from $33.3 million in Q3 2024.
• Revenue increased 6% sequentially from the second quarter of 2025, primarily driven by growth in patients and sales of IMCIVREE for Bardet-Biedl syndrome (BBS).
• U.S. revenue was $38.2 million (74% of product revenue), increasing 19% sequentially, while revenue outside the U.S. was $13.1 million (26% of product revenue), a sequential decrease of $3.4 million or 21%.
• A one-time charge of $3.2 million was recorded in Q3 2025 due to a final reimbursed price agreement for IMCIVREE in France, with $2.6 million relating to periods prior to Q3 2025.
• The FDA accepted the supplemental new drug application (sNDA) for setmelanotide in acquired hypothalamic obesity (HO) and granted Priority Review, setting a PDUFA goal date of December 20, 2025.
• Preliminary results from the setmelanotide Phase 2 trial in Prader-Willi syndrome are expected in the fourth quarter of 2025.
• A German observational study showed setmelanotide treatment was associated with improvement in measures of metabolic dysfunction-associated steatotic liver disease (MASLD) and kidney function in BBS patients.
• Cash, cash equivalents, and short-term investments totaled approximately $416.1 million as of September 30, 2025, up from $320.6 million as of December 31, 2024.
• Net loss attributable to common stockholders was ($54.3) million for Q3 2025, or ($0.82) per basic and diluted share, compared to ($45.0) million, or ($0.73) per share, for Q3 2024.
• Full-year 2025 Non-GAAP Operating Expenses are anticipated to be between $295 million and $315 million.
• Current cash, cash equivalents, and short-term investments are expected to fund planned operations for at least 24 months.

Sentiment

Score: 7

Explanation: The company shows strong revenue growth for its key product, IMCIVREE, and significant progress in its clinical pipeline with an upcoming FDA decision for a new indication. While net loss increased, it's typical for a growing biopharma company investing in R&D and commercial expansion. The strong cash position provides a solid runway for future operations.

Positives

• Net product revenue increased to $51.3 million in Q3 2025 from $33.3 million in Q3 2024, demonstrating strong year-over-year growth.
• Sequential revenue growth of 6% from Q2 2025, primarily driven by Bardet-Biedl syndrome (BBS) commercial efforts.
• U.S. revenue showed robust sequential growth of 19% to $38.2 million, representing 74% of total product revenue.
• The FDA accepted the sNDA for setmelanotide in acquired hypothalamic obesity (HO) and granted Priority Review, indicating a faster review timeline.
• A PDUFA goal date of December 20, 2025, has been set for the HO sNDA, providing a clear timeline for a potential approval decision.
• The European Medicines Agency (EMA) confirmed validation of the Type II variation submission for setmelanotide for the same HO indication.
• A German observational study published in the Journal of Clinical Endocrinology & Metabolism showed setmelanotide improved measures of MASLD and kidney function in BBS patients.
• The company maintains a strong cash position of $416.1 million as of September 30, 2025, which is expected to fund operations for at least 24 months.
• Net loss attributable to common stockholders for the nine months ended September 30, 2025, decreased to ($153.1) million from ($219.9) million in the prior year period.

Negatives

• Net loss attributable to common stockholders increased to ($54.3) million in Q3 2025 from ($45.0) million in Q3 2024.
• Net loss per basic and diluted share increased to ($0.82) in Q3 2025 from ($0.73) in Q3 2024.
• Revenue from outside the United States decreased sequentially by $3.4 million or 21% to $13.1 million, affected by a one-time charge and variability in ordering patterns.
• A one-time $3.2 million charge was recorded in Q3 2025 due to a final reimbursed price agreement in France, with $2.6 million relating to periods prior to Q3 2025.
• Research and development (R&D) expenses increased to $46.0 million in Q3 2025 from $37.9 million in Q3 2024, primarily due to increased headcount and stock-based compensation.
• Selling, general, and administrative (SG&A) expenses increased to $52.4 million in Q3 2025 from $35.4 million in Q3 2024, driven by higher headcount, stock-based compensation, and marketing costs.

Risks

• Ability to enroll patients in clinical trials.
• The design and outcome of clinical trials.
• The impact of competition.
• The ability to achieve or obtain necessary regulatory approvals.
• Risks associated with data analysis and reporting.
• Unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives.
• Risks associated with the laws and regulations governing international operations and the costs of any related compliance programs.
• The ability to successfully commercialize setmelanotide.
• Liquidity and expenses.
• The ability to retain key employees and consultants, and to attract, retain, and motivate qualified personnel.
• General economic conditions.

Future Outlook

Rhythm Pharmaceuticals anticipates several key milestones, including preliminary Phase 2 results for setmelanotide in Prader-Willi syndrome in Q4 2025, an FDA decision for acquired hypothalamic obesity by December 20, 2025, and topline data from multiple Phase 3 trials in Q1 2026. The company also plans to initiate a pivotal Phase 3 trial for bivamelagon in acquired hypothalamic obesity in 2026. Financial guidance for full-year 2025 Non-GAAP Operating Expenses is set between $295 million and $315 million, with current cash expected to fund operations for at least 24 months.

Management Comments

• "Rhythm delivered continued momentum during the third quarter, highlighted by the FDA acceptance of our supplemental new drug application (sNDA) for acquired hypothalamic obesity (HO) and steady growth from our Bardet-Biedl syndrome (BBS) commercial efforts."
• "With the FDAs PDUFA goal date on HO on December 20, a strong cash position and continued progress across our melanocortin-4 receptor (MC4R) pathway pipeline, the Company is well positioned to deliver sustained, long-term growth."

Industry Context

Rhythm Pharmaceuticals operates in the specialized field of rare neuroendocrine diseases, focusing on the melanocortin-4 receptor (MC4R) pathway. The progress with IMCIVREE (setmelanotide) for Bardet-Biedl syndrome and the potential approval for acquired hypothalamic obesity position the company as a leader in this niche. The development of additional MC4R agonists like RM-718 and bivamelagon, alongside preclinical work for congenital hyperinsulinism, indicates a strategy to expand its pipeline within this therapeutic area. The focus on genetic etiologies for obesity and related metabolic disorders aligns with a broader industry trend towards precision medicine and targeted therapies for rare diseases.

Stakeholder Impact

• Shareholders: Potential for increased value due to growing revenue, pipeline progress, and upcoming regulatory decisions. Increased net loss and operating expenses could be a concern, but strong cash runway mitigates immediate financial risk.
• Patients: Continued access to IMCIVREE for existing indications and potential new treatment options for acquired hypothalamic obesity and Prader-Willi syndrome.
• Employees: Increased headcount and expanding business operations suggest job stability and growth opportunities.
• Regulatory Authorities: Ongoing engagement with FDA and EMA for sNDA and MAA submissions.

Next Steps

• Disclose preliminary results from the Phase 2 trial evaluating setmelanotide in Prader-Willi syndrome in the fourth quarter of 2025.
• Receive a decision from the FDA on the sNDA for setmelanotide in conditions associated with acquired hypothalamic obesity by December 20, 2025.
• Complete enrollment in the Phase 1, Part C trial evaluating the weekly, MC4R agonist RM-718 in patients with acquired hypothalamic obesity in the first quarter of 2026.
• Announce topline data in the 12-patient Japanese cohort of the setmelanotide Phase 3 trial in acquired hypothalamic obesity in the first quarter of 2026.
• Announce topline data in the Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in the first quarter of 2026.
• Complete enrollment in the setmelanotide Phase 3 trial substudy in congenital hypothalamic obesity in the first half of 2026.
• Pending further feedback from U.S. and European regulatory agencies, initiate a pivotal Phase 3 trial evaluating bivamelagon in acquired hypothalamic obesity in 2026.

Key Dates

Recommendation

While Rhythm Pharmaceuticals demonstrates strong revenue growth for IMCIVREE and significant progress in its clinical pipeline, particularly with the upcoming FDA decision for acquired hypothalamic obesity, the company continues to operate at a net loss due to substantial R&D and SG&A investments. The strong cash position provides a good runway, but the stock's performance will heavily depend on the success of its pipeline, especially the regulatory outcome for HO and future clinical trial results. Given the mix of positive commercial momentum and ongoing high investment with future catalysts, a 'hold' recommendation is appropriate for investors awaiting further clarity on pipeline success and path to profitability.

Keywords

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, Bardet-Biedl syndrome, BBS, hypothalamic obesity, HO, Prader-Willi syndrome, PWS, MC4R agonist, rare neuroendocrine diseases, biopharmaceutical, Q3 2025 earnings, FDA approval, sNDA, PDUFA, clinical trials, RM-718, bivamelagon, MASLD, kidney function, financial results